PT - JOURNAL ARTICLE AU - Ulgen, Ayse AU - Gürkut, Özlem AU - Li, Wentian TI - Potential Predictive Factors for Breast Cancer Subtypes from a North Cyprus Cohort Analysis AID - 10.1101/19010181 DP - 2020 Jan 01 TA - medRxiv PG - 19010181 4099 - http://medrxiv.org/content/early/2020/12/24/19010181.short 4100 - http://medrxiv.org/content/early/2020/12/24/19010181.full AB - Purpose We present a first epidemiological survey from North Cyprus to determine predictive factors for breast cancer subtypes.Methods More than 300 breast cancer patients, 90% of them having subtype information, are surveyed from the State Hospital in Nicosia between 2006 – 2015 for their demographic, reproductive, genetic, epidemiological factors. The breast cancer subtypes, Estrogen receptor (ER) +/-, Progesterone receptor (PR) +/-, and human epidermal growth factor 2 (HER2) +/- status, are determined. Single and multiple variable, regularized regressions, with predictive factors as independent variables, breast cancer subtypes as dependent variables are conducted.Results Our cohort differs significantly from larger cohorts (e.g., Breast Cancer Family Registry), in age, menopause status, age of menarche, parity, education, oral contraceptive use, breastfeeding, but the distribution of breast subtypes is not significantly different. Subtype distribution in our cohort is also not different from another Turkish cohort. We show that the ER+ subtype is positively related to age/post-menopause; ER+/PR+ is positively associated with age, but negatively associated with cancer stage; HER2+, which is negatively correlated with ER+ and ER+/PR+, is positively related to cancer stage but negatively associated with age/post-menopause.Conclusion Assuming ER+ and ER+/PR+ to have better prognostic, HER+ to have worse prognostic, then older age and postmenopause seem to be beneficial, smoking and family history of cancer seem to be detrimental. Next steps include looking at potential biomarkers and using cure models to determine long-term survivors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAU was supported by Fullbright Visiting Research Scholarship Grant from the US Department of State.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not Applicableindividual person's data is not available. summary data is available upon request.